GHZ339

GHZ339 is an investigational substance being studied for the treatment of moderate to severe atopic dermatitis, a chronic inflammatory skin condition also known as eczema. It has no marketing authorisation in the registry records, meaning it is not yet approved as a medicine. The substance is given by subcutaneous injection in the clinical trial setting.^[1]

What is GHZ339?

GHZ339 is an investigational medicine under evaluation in a Phase 2 platform study. The trial record does not state its chemical class or mechanism of action. The substance is administered by subcutaneous injection, which means it is given under the skin.^[1] The trial also includes topical comparators: pimecrolimus and tacrolimus, which are calcineurin inhibitors used on the skin for atopic dermatitis.^[1]

How does GHZ339 work?

The registry record does not describe the mechanism of action of GHZ339. No supplementary sources were provided to explain how the substance works at a molecular level. What is known from the trial design is that GHZ339 is given by subcutaneous injection, while the comparator medicines pimecrolimus and tacrolimus are applied topically to the skin.^[1]

Which conditions is GHZ339 being studied for?

• Moderate to severe atopic dermatitis — a long-lasting inflammatory skin disease that causes dry, itchy skin and rashes. The trial focuses on people whose disease is moderate to severe, meaning it has a significant impact on daily life.^[1]

How is GHZ339 given?

In the clinical trial, GHZ339 is administered by subcutaneous injection, which means it is injected under the skin.^[1] The dose is not reported in the registry record. The comparator medicines pimecrolimus and tacrolimus are given as topical formulations, applied directly to the skin.^[1]

What do the clinical trials show?

There is one registered clinical trial for GHZ339: a Phase 2 platform study evaluating the efficacy and safety of investigational compounds, including GHZ339, in patients with moderate to severe atopic dermatitis.^[1] The trial is currently authorised, meaning it has received approval to proceed but may not yet be recruiting participants.^[1]

What is the trial measuring?

The primary outcome is the percentage change from baseline in the EASI score at Week 16. The EASI score, or Eczema Area and Severity Index, is a standard tool used by doctors to measure the extent and severity of atopic dermatitis. A larger percentage reduction in the EASI score indicates greater improvement in the skin condition.^[1] The study aims to establish and characterise the dose-response relationship of GHZ339 and estimate the treatment effect compared with placebo on this measure.^[1]

Who can take part in the trial?

The trial plans to enroll 228 participants with moderate to severe atopic dermatitis.^[1] The registry record does not list detailed eligibility criteria such as age limits or specific exclusion criteria. The study is interventional, meaning participants receive one of the study treatments and are followed over time.^[1]

What side effects are known?

No side effect information is available in the registry record for GHZ339, and no supplementary sources were provided. The safety profile of GHZ339 is being evaluated in the ongoing Phase 2 trial.^[1]